SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " 55 million " 43 found 🔀 AI-powered Shuffle
Yankees' David Bednar Gets $55 Million Contract Prediction
The New York Yankees have some key players hitting the open market this offseason
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. The open-label Krascendo 1 trial enrolled 338 people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Patients who had already received a KRAS G12C inhibitor or pan-KRAS/RAS inhibitor were excluded from the trial. Participants received either divarasib once daily, Lumakras once daily or Krazati twice daily. Roche announced back in July that divarasib had demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS), meeting the trial’s primary and key secondary endpoints. But the Swiss pharma had been holding back the detailed data until now. At the European Society for Medical Oncology (ESMO) Congress in Madrid, Roche revealed that median OS for the 167 patients who received divarasib was 17.7 months, compared to 12 months for the 171 patients who received Lumakras or Krazati. The benefit was similarly clear when it came to median PFS, which stood at 9.8 months versus 5.7 months, respectively. A total of 44% of patients receiving divarasib were alive without disease progression at one year, compared to 24% of the control group, according to Roche’s presentation. It was a similar story for the objective response rate, which came in at 58% for divarasib versus 32% for the control group, while median duration of response was 11.9 months versus 6.9 months. Stefan Frings, M.D., Ph.D., deputy chief medical officer at Roche Pharma, told Fierce that the data made for a “very comprehensive, strong package, which should be convincing to health authorities.” “It’s an important advance for patients with lung cancer,” Frings said in an interview at a Madrid hotel during the conference. “It's a second-line setting, and patients who receive divarasib benefit compared to the current first-generation KRAS G12C inhibitors by having far longer overall survival,” he continued. “They live longer. They have better progression-free survival, better response rates, and with a safety profile which is—if [anything]—even better,” he said. According to Roche, 4.8% of patients receiving divarasib discontinued treatment due to treatment-related adverse events, compared to 11.7% in the control group. Serious treatment-related adverse events were also less common with divarasib, at 7.8% versus 15.2%. Roche’s confidence in divarasib had been building even before this phase 3 success. The candidate had already shown better potency and selectivity than the incumbent KRAS G12C inhibitors Krazati and Lumakras in preclinical tests. After cross-trial comparisons suggested that the edge translated into better clinical outcomes, Roche axed a study comparing divarasib to the chemotherapy docetaxel and went toe-to-toe with Lumakras and Krazati. “We designed the drug on purpose with higher potency and better selectivity,” Frings explained. “So, based on preclinical models, we clearly knew it would be superior to the first generation.” “It’s honestly not so frequent that pharma companies go head-to-head,” he added. “But if you want to make a point, if you want to convince payers, prescribers and patients … then a head-to-head win is rather rewarding.” While Amgen and BMS reached the regulatory finish line first for KRAS G12C-mutated, locally advanced or metastatic NSCLC in 2021 and 2022, respectively, they have struggled to capitalize on their head start. Krazati brought in $55 million for BMS in the second quarter, while Lumakras delivered $111 million to Amgen. For its part, Roche is aiming for peak divarasib sales of 1 billion to 2 billion Swiss francs ($1.2 billion to $2.5 billion), according to Frings. The Big Pharma is currently recruiting patients into a phase 3 trial comparing divarasib plus Keytruda against Keytruda plus chemotherapy in previously untreated advanced or metastatic nonsquamous KRAS G12C-mutated NSCLC. Roche has previously suggested that sales in metastatic disease would account for most of the forecast. Frings was tight-lipped on the exact timeline for a regulatory filing but said the Swiss pharma is “certainly keen to get this to as many patients as possible around the world.” Roche has more RAS drugs coming up behind divarasib. The pharma has already launched phase 1 trials of a pan-RAS inhibitor called RG6505 and a KRAS G12D inhibitor dubbed RG6620 in solid tumors. Roche’s partner Chugai Pharmaceutical is also testing a pan-KRAS inhibitor called AUBE00. Roche has made a “deliberate effort” to test a range of RAS drugs, Frings said. “If you have many rare mutations and you are scrambling to find sufficient patients, a pan-RAS inhibitor makes a lot of sense,” he explained.
Jalen Hurts’ Health Scare Puts NFL’s Relentless Expectations Into Perspective
Six days ago, the conversation surrounding Jalen Hurts was about football. His $255 million contract, Philadelphia's offensive struggles, and whether he was playing well enough to justify the enormous expectations that come with being a franchise quarterback. Those were fair questions. They still are, at least from a football standpoint. But Monday's news that Hurts …
Jalen Hurts’ Health Scare Puts NFL’s Relentless Expectations Into Perspective
Six days ago, the conversation surrounding Jalen Hurts was about football. His $255 million contract, Philadelphia's offensive struggles, and whether he was playing well enough to justify the enormous expectations that come with being a franchise quarterback. Those were fair questions. They still are, at least from a football standpoint. But Monday's news that Hurts …
$55 million gift to fund Marietta College housing, health sciences facility
MARIETTA — Marietta College plans to renovate three first-year residence halls, remove several campus buildings and open a graduate health sciences facility on Fourth Street with support from a $55 million gift commitment from Joe and Linda Chlapaty. President Kathleen Poorman Dougherty announced the commitment Friday during her State of the College address, held during […]
Stellantis supplier Dakkota to close Detroit plant, lay off 397
The plant opened in 2019 with a $55 million investment to supply the Jeep Grand Cherokee and Dodge Durango.
Greenwich five-unit apartment building sells for $2.55M
A five-unit apartment building in Greenwich has sold for $2.55 million, or $510,000 per unit, according to town land records.
Museum of Science opens another immersive venue for live events
The 10,000-square-foot William and Charlotte Bloomberg Public Science Common was supported by a $155 million gift from Bloomberg Philanthropies. It can transform into an immersive environment with video projections and movable LED walls.
Mobile area health systems receive grants from state rural health program
34 grants total nearly $55 million
$55 million student wellness center project breaks ground at Michigan Tech
Features include a UP Health System - Portage supported urgent health care clinic, a fitness floor and therapy offices.
Nearly $55 million awarded to boost healthcare access across rural Alabama
Gov. Kay Ivey announced that 34 grants totaling nearly $55 million are being awarded to healthcare providers and institutions throughout Alabama as part of the second round of the Alabama Rural Health Transformation Program (ARHTP) funding for 2026.
Alabama Awards Nearly $55 Million in Additional Rural Health Grants
Alabama Awards Nearly $55 Million in Additional Rural Health GrantsMONTGOMERY, Ala. — Alabama Gov. Kay Ivey announced Thursday that 34 grants totaling nearly $5
Governor Ivey Announces Additional Alabama Rural Health Transformation Program Grants Totaling Nearly $55 Million -
MONTGOMERY – Governor Kay Ivey on Thursday announced the awarding of 34 grants totaling nearly $55 million to healthcare providers and institutions throughout the state as part of the second round of Alabama Rural Health Transformation Program (ARHTP) funding for 2026. … Continued
Detroit Pistons: How Ausar Thompson’s Deal Compares Across NBA
The Detroit Pistons signed Ausar Thompson to a five-year, $155 million rookie scale extension on Friday
Virginia casinos’ August take is $97.6M
August gaming revenues at Virginia’s three permanent casinos and temporary casinos in Petersburg and Norfolk totaled $97.55 million.
Michael Bloomberg Gives $155 Million to Museum of Science, Boston for New Civic Wing
Michael Bloomberg has donated $155 million to the Museum of Science, Boston through Bloomberg Philanthropies, funding a new public venue designed to bring... Read More
Michael Bloomberg honors his late parents with $155 million donation
Michael Bloomberg donated $155M to Museum of Science Boston. Plus, Ballmer gave $125M for children's behavioral health research.
What to know about the new Museum of Science wing opening in October
The 10,000-square-foot, $155 million venue will have state-of-the-art technology.
Applyrs addresses Albany mid-year report laying out deficits
Albany’s mid-year report puts the city’s financial challenge at $55 million over the next 16 months.
Singapore's UOB to shed asset management arm for $433.5 million to focus on wealth management
Singapore lender United Overseas Bank said on Wednesday that it had agreed to sell its asset management business to a unit of European insurer Allianz for S$555 million ($433.49 million).
'Spider-Man: Brand New Day' scores second-largest global opening ever
"Spider-Man: Brand New Day" swung into the top spot at the box office and scored one of the highest-grossing opening weekends with an estimated haul of $355 million in the
‘Spider-Man: Brand New Day’ nets second best North American opening ever with $355 million
“Spider-Man: Brand New Day” has made box office history in its first weekend, becoming the second biggest North American opening ever with $355 million in ticket sales. It was just
‘Spider-Man: Brand New Day’ nets second best North American opening ever with $355 million
“Spider-Man: Brand New Day” has made box office history in its first weekend, becoming the second biggest North American opening ever with $355 million in ticket sales.
‘Spider-Man: Brand New Day’ nets second best North American opening ever with $355 million
“Spider-Man: Brand New Day” has made box office history in its first weekend, becoming the second biggest North American opening ever with $355 million in ticket sales.
England's Elliot Anderson Joins Manchester City In $155 Million Transfer
Manchester City officially completed the signing of England midfielder Elliot Anderson from Nottingham Forest on Thursday for a reported 116 million pounds ($155 million).
Rice spinout company receives Small Business Innovation Research award
LumiStrain, a Rice spinout commercializing a Strain Sensing Smart Skin (S4) for structural testing and health monitoring, has received a $1.55 million award through the National Science Foundation’s Small Business Innovation Research Fast-Track program.
Eclipse Business Capital Provides $55MM ABL Credit Facility to Food & Beverage Industry
Eclipse Business Capital (EBC) provided a $55 million asset-based lending credit facility to a premier frozen food supplier.
“Toy Story 5 ”soars past “Supergirl”'s bumpy $38 million takeoff at the box office
D.C. and Warner Bros. were hoping for a $50–55 million return on their $170 million investment into the standalone supheroine flick.
Heastie: State budget includes additional funding for Buffalo
State Assembly Speaker Carl Heastie said at least $55 million is coming to Buffalo, including $30 million in Temporary Municipal Assistance.
Pop star Shakira is acquitted in a Spanish tax fraud case
A Spanish court has acquitted Shakira of tax fraud and ordered the government to return over 55 million euros in fines and interest. The decision, seen Monday by The Associated
City Council panel backs tax incentives for United Center entertainment district
A plan to provide nearly $55 million in tax rebates for the $7 billion project that’s meant to be “transformative” for the West Side sailed through the council’s economic development committee.
City Council panel backs tax incentives for United Center entertainment district
A plan to provide nearly $55 million in tax rebates for the $7 billion project that’s meant to be “transformative” for the West Side sailed through the council’s economic development committee.
March hiring surge indicates a job market firming up
Employers hired 5.55 million people in March, a stunning rise of 655,000 from February.
House passes tax package to end $555 million in business tax breaks | The Sum and Substance
Four bills roll back state tax breaks or decouple from federal tax incentives in order to raise revenue for a new Family Affordability Credit.
Roglieri's lawyer blames his $55 million theft on bad 'business model'
Loan broker Kris Roglieri argues before sentencing that bad “business model” led him to steal $55 million from clients.
Telefonica Posts Wider Net Loss, Revenue Rises; Dividend Declared
The result partly reflects around 255 million euros in impairments and losses from disposed assets in the quarter, including other noncash goodwill impairments.
Exclusive | Garden City Equity Raises $255 Million From Business Figures, Musicians and Athletes
Backers of the company include former Intel CEO Pat Gelsinger, former Florida Gov. Jeb Bush and ex-NFL quarterback Drew Brees.
Nintendo Switch becomes gaming giant's best-selling console in history
The Super Mario maker said 155 million units of the console have now been sold overall.
I swore I'd never join the family business
David Heacock left a $2 million Wall Street career to buy his family business and grow it into Filterbuy, a $255 million company.
I bought a company with my credit card. Twenty years later, it generated $55 million in global sales.
Teresa Johnson shares how a leap of faith on a pottery studio grew into Color Me Mine, now earning $55 million and transforming her family's future.
Counteracting the Market Dominance That Keeps Health Care So Expensive
Research by UCLA Luskin’s Wesley Yin is one of several projects made possible by nearly $55 million in awards to the school.
Michele Kang takes on women’s sports’ most neglected need
With a $55 million pledge, Kang is committing to research the women’s sports world has waited decades for.
Michele Kang launches institute with U.S. Soccer to advance women’s sports research
Kang previously announced two separate investments in U.S. Soccer totaling $55 million.